A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...
After hours: January 29 at 6:03:56 PM EST Loading Chart for RAMP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback